Company Aggregate Debt: harvardbioscience.com (HBIO)

Harvard Bioscience is implementing automation into infusion systems and monitoring, supplementing them with microfluidic chips for unbiased drug testing. The amount of debt obligations in the GURU.Markets chart reflects capital dynamics, where the 0.04 mark shows the current state. Growth prospects are linked to the integration of robotic manipulators and laser control, which minimizes production defects.

Company Aggregate Debts: Harvard Bioscience, Inc. (HBIO) for 07/04/2022 - 10/27/2026

Metric breakdowns and analytics for Harvard Bioscience (HBIO)

- price and consensus price forecast:

Market Price Harvard Bioscience Inc.|HBIO - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Harvard Bioscience|HBIO - Enterprise Value

- book capitalization data:

Net Assets per Share Harvard Bioscience|HBIO - Book Capitalization|Market Cap to Net Assets Ratio harvardbioscience.com|HBIO - Company Total Assets

- debt and liquidity data:

Total Debt to Capital Harvard Bioscience|HBIO - Long-Term Debt to Equity|Short-Term Debt to Equity harvardbioscience.com|HBIO - Company Total Debt|Debt to Net Assets Ratio Harvard Bioscience

Basic company analysis:HBIO Harvard Bioscience Inc.

Stable demand for equipment within the B2B ecosystem of Harvard Bioscience (HBIO) makes the company attractive for long-term investment. The debt_co metric aggregates all credit obligations, while the debt movement chart with a current value of 0.04 allows for a real-time assessment of the actual volume of liabilities relative to operational stability. Analyzing this indicator helps determine whether credit leverage serves as a growth tool or a risk to the business's solvency.

Key competitors